On January 21, 2026, Johnson & Johnson announced fourth-quarter results that exceeded Wall Street expectations, marking another solid quarter for the pharmaceutical and medtech powerhouse. The earnings beat, combined with management's bullish outlook on future cash flow generation, presents a